Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
top of page
Browse by category
Search
Browse by tag
bottom of page